Company: EUDAW
Filing Date: 2025-04-29
Form Type: 20-F
Source: 0001641172-25-006627
Chunk: 1

Company: EUDA Health Holdings Ltd
Filing Date: 2025-04-29
Form: 20-F
Item: Item 3
Chunk 1
---
2, 2023 (inception) through December 31, 2023 contains an explanatory
paragraph that expresses substantial doubt about FCL’s ability to continue as a going concern. FCL had no operations or assets
other than CK Health which is a start-up company that has no operations prior to April 1, 2024 other than start up activities. As of
the date of this report, CK Health has signed two agency contracts giving it the exclusive rights to distribute certain collagens of
“ YOROYAL” brand in Malaysia, Vietnam and Indonesia, and certain bioenergy cabins in Malaysia. CK Health is a new
company with an unproven business plan with risks inherent in sales of retail products and use of agents paid on commissions based
on sales. If this new business fails, it could result in material financial and reputational harm to the Company. As a result, the
value of our shares could decline substantially and investors may lose part or all of their investments.

   3  

CK Health has no experience in direct
sales of stem cell therapy services rendered in China. There could be risks inherent in this new line of business that is not yet known
to us at this time.

On April 22, 2025, CK Health
entered into a collaboration agreement with Key Lock Health Management Co., Ltd. (“ Key Lock”), an authorized distributor
of Guangdong Cell Biotech Co. Ltd. (“ Guangdong Cell Biotech”), a prominent player in stem cell therapies and regenerative
medicine, that develops autologous cell treatments and tailored medicines for various disorders. Key Lock is responsible for promoting
and selling Guangdong Cell Biotech’s stem cell therapy packages, managing sales, market development and customer support. Pursuant
to the collaboration agreement with Key Lock, CK Health will purchase from Key Lock certain stem cell therapy services offered by Guangdong
Cell Biotech at certain pre-determined prices and market and sell these services in Singapore and Malaysia; and Key Lock will use its
commercial endeavours to ensure proper stem cell therapy services received by EUDA customers at one of Guangdong Cell Biotech’s
treatment centers in China. CK Health has no experience in direct sales of stem cell therapy services. Since these therapy services will
be rendered in third-party treatment centers in China, there could be risks inherent in this new line of business that is not yet known
to the Company at this time. CK Health does not have the exclusive right to sell Guangdong Cell Biotech